Dr. Peter Edward Barwick, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 10 Haven Dr, Granby, CT 06035 Phone: 180-653-3023 |
News Archive
Researchers from the University of Copenhagen have studied what it means for children to have parents who are refugees and have PTSD.
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.
Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.
SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.
› Verified 5 days ago